Business Context and Reporting Period
This Form 8-K is a current report filed by Stellar Biotechnologies, Inc. on September 27, 2018. The filing addresses corporate governance changes effective September 28, 2018, and October 1, 2018.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
- Director Departure: Daniel E. Morse, Ph.D., notified the Company of his decision to retire from the Board of Directors effective September 28, 2018, citing health reasons.
- Board Size Reduction: On October 1, 2018, the Board resolved to decrease its size from eight to seven directors, effective upon Dr. Morse's retirement.
- Reason for Departure: The filing explicitly states the retirement is not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific event of the director's retirement.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Morse's retirement (September 28, 2018).
- Verify the new Board composition and size (reduced to seven directors).
- Review subsequent filings to ensure no undisclosed disagreements arose regarding the departure.